Clinical trials have substantiated the efficacy of these agents in fostering weight loss, bringing a ray of hope for individuals grappling with obesity
This effect reduces your appetite and overall food intake, making them effective as part of weight loss programs
Practice Pearl(s) The dosing regimen of glucagon-like peptide-1 (GLP-1) agonists is characterized by careful initiation and titration to ensure optimal glycemic control while minimizing potential adverse effects
The secondary outcomes comprising cardiometabolic risk factors (including high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), body mass index (BMI), insulin sensitivity index adjusted for BMI (ISI), systolic blood pressure (SBP), diastolic blood pressure (DBP)) [33] and multiple-organ complications (liver diseases: metabolic dysfunction-associated steatohepatitis, liver fibrosis, fibrosis in MASLD, liver cirrhosis, hepatocellular carcinoma (HCC), hepatic failure
But they arent, and every doctor and nurse practitioner who follows me on social media knows that it is hard to pay the bills by accepting insurance for menopause care (this is also the same in Canada, given the dismal reimbursement from the provincial health plans)
This is where things get tricky
